As a network member, Pfizer gains access to data from various global healthcare organizations. The platform provides users with de-identified patient data integrated from EMRs, tumor registries, unstructured pathology reports, and molecular genomics data to support clinical study and protocol design, as well as site identification and patient recruitment.
“TriNetX is becoming the defacto platform for clinical research,” said Gadi Lachman, CEO of TriNetX.
The company’s global health research network includes more than 70 healthcare organizations globally. Currently, TriNetX is working with more than 25 of the top pharmaceutical companies, Lachman examined.
Dr. Mohanish Anand, head of study optimization at Pfizer said the company joined TriNetX “to harness real world data for clinical trial optimization, with the goal of accelerating our ability to bring new therapies to market.”
“Pfizer will use the real-time access to clinical, genomic and oncology data to design clinical trial protocols with greater efficiency. For example, we hope to reduce avoidable amendments by identifying and correcting overly restrictive inclusion and exclusion criteria early in the design process,” Anand explained in a press release.
TriNetX recently announced a new algorithm designed to further support clinical trial patient identification. The chemotherapy lines of treatment identification algorithm is able to understand treatment patterns, according to the company, which announced the new offering at the SCOPE Summit in February.
“We remain focused on developing new features and functionality to drive clinical trial optimization,” Lachman added.